Microwave Assisted, One Pot Synthesis of Alkyl-3-amino-2-arylimino-1,3-thiazolan-4-ones-5-ylidene Acetate

KH. POURSHAMSIAN*, N. MONTAZERI, S. AHAMADI and T. NOGHANI

Department of Chemistry, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran

*Corresponding author: E-mail: kh_pourshamsian@toniau.ac.ir

(Received: 4 November 2011;

Accepted: 23 July 2012)

AJC-11868

Reaction of 4-phenylthiosemicarbazide and thiosemicarbazide with dialkyl acetylene dicarboxylate in CH_2Cl_2 at microwave irradiation lead to alkyl-3-amino-2-phenyliminothiazolidine-4-one-5-ylidene acetate and alkyl-3-amino 2-iminothiazolidine-4-one-5-ylidene acetate in moderate yields and short times. Di-*t*-butylacetylenedicarboxylate have a different treatment and the cyclization products is not observed. The structures of the synthesized compounds were elucidated by elemental analysis and spectral data.

Key Words: Microwave irradiation, Thiazolidine-4-one, 4-Phenylthiosemicarbazide, Thiosemicarbazide.

INTRODUCTION

The synthesis of the thiazolidin-4-one scaffold is gaining considerable attention due to the fact that its derivatives have shown a wide spectrum of activities. Thiazolidine-4-ones are important building blocks in pharmaceutical agent and biologically active products¹⁻⁵. Several substituted thiazolidinones have been found to possess hypnotic, anaesthetic, sedative, anticonvulsant and microbiological activities⁶⁻⁹. Some thiazoline-4-ones derivatives are reported as human immunodeficiency virus-1 (HIV-1) non-nucleoside reverse transcriptase inhibitors (NNRTIs) or anticancer activities and can inhibit cell division¹⁰⁻³⁰. In view of the various physiological activities of thiazolidinones, many thiazolidinone derivatives have been prepared and several new methods for the preparation of substituted thiazolidine-4-one have been recently reported³¹⁻³⁴. However, these methods have several drawbacks, namely, the need for a high reaction temperature and long reaction time. The development of mild and efficient methods is still desired. We present here a mild and efficient method to give 2-iminothiazolidine-4-ones-5-ylidene acetate in good yields and short times.

EXPERIMENTAL

Compounds were obtained from merck and used without further purification. The melting points were taken on an electrothermal 9100 capillary melting point apparatus and are uncorrected. Thin-layer chromatographies were performed using HF_{254} fluorescent silica gel plates (Merck), which were examined under UV 254 and 365 nm light. Infrared spectra

(v/cm^{-1}) were recorded on Shimadzu IR-470, using KBr disks. ^1H and ^{13}C NMR spectra were recorded on DRX-500 MHz NMR Spectrometer at 293 K in CDCl_3 . Spectra were internally referenced to TMS. Peaks are reported in ppm downfield of TMS. Elemental analyses for C, H and N were performed using a Heraeus CHN-O-Rapid analyzer. All microwave irradiation experiments were carried out in a dedicated CEM-Discover monomode microwave apparatus, operating at a frequency of 2.45 GHz with continuous irradiation of 300 W maximum power.

Synthesis of (3a-d): 4-Phenylthiosemicarbazide (2 mmol) (**1a**) was mixed with dialkyl acetylenedicarboxylate (2 mmol) in dry CH_2Cl_2 (5 mL) and irradiated in a microwave oven at 300 W for 10 min. Then the reaction mixture was cooled and recrystallized with ethanol. The pure products identified as alkyl-3-amino-2-phenyliminothiazolidine-4-one-5-ylidene acetate (**3a**) in reasonable yields (**Scheme-I**).

Scheme-I: Synthesis of alkyl-3-amino-2-phenyliminothiazolidine-4-one-5-ylidene acetate

In the same method thiosemicarbazide reacted with dialkyl acetylenic esters and produce the same derivatives of thiazolidin-4-ones (**3c-3d**) in excellent yields (**Scheme-I**).

Surprisingly di-*tert*-butyl acetylene dicarboxylate have different treatment and instead of cyclization product, we isolated condensation product and thiosemicarbazone derivatives are chief products (**Scheme-II**).

Scheme-II: Product of 4-Phenylthiosemicarbazide and thiosemicarbazide with di-*tert*-butyl acetylene dicarboxylate

RESULTS AND DISCUSSION

In our continuous approach toward developing biologically active heterocyclic synthesis *via* acetylenic esters-based reactions involving CH-, NH- or OH-acid compounds³⁰⁻³⁴, herein we wish to explain an expedient method for construction of some novel 2-imino-thiazolidine-4-one-5-ylidene acetate derivatives (**3**) from one-pot reaction between 4-phenylthiosemicarbazide (**1a**) and thiosemicarbazide (**1b**) with appropriate acetylenic esters (**2**) in good yields (**Scheme-I**).

Methyl-3-amino-2-Phenylimino-4-oxo-1,3-thiazolan-5-ylidene acetate (3a): Pale yellow crystals; yield: 72 %, m.p. 162-163 °C. IR (KBr, $\nu_{\max}$, cm^{-1}): 3316, 3125 (NH_2), 1728, 1635 ($2\text{C}=\text{O}$), 1684 ($\text{C}=\text{C}$), 1610 ($\text{C}=\text{N}$). ^1H NMR: δ = 3.80 (s, MeO), 4.79 (s, NH_2), 7.08 (s, CH), 7.13-7.66 (5H, Ph) ppm. ^{13}C NMR: δ = 168.1, 160.1 ($2\text{C}=\text{O}$), 152.6 ($\text{C}=\text{N}$), 143.1 (C), 136.2 (C), 128.1 (2CH), 126.8 (CH), 123.7 (2CH), 114.3 (CH), 51.0 (MeO) ppm. MS: m/z (%) = 277 (28, M^+), 160 (8), 142 (1), 117 (23), 85 (86), 77 (100), 58 (63), 44 (24). Anal. calcd. for $\text{C}_{12}\text{H}_{11}\text{N}_3\text{O}_3\text{S}$ (277.24): C, 51.19; H, 3.96; N, 15.14 %. Found: C, 51.71; H, 3.77; N, 15.43 %.

Ethyl-3-amino-2-phenylimino-4-oxo-1,3-thiazolan-5-ylidene acetate (3b): Pale yellow powder; yield: 72 %, m.p.: 162-164 °C. IR (KBr, $\nu_{\max}$, cm^{-1}): 3309, 3146 (NH_2), 1719, 1642 ($2\text{C}=\text{O}$), 1688 ($\text{C}=\text{C}$), 1593 ($\text{C}=\text{N}$). ^1H NMR: δ = 1.38 (t, $^3J_{\text{HH}} = 7.3$, Me), 4.18 (q, $^3J_{\text{HH}} = 7.2$, CH_2O), 4.55 (brs, NH_2), 6.78 (s, CH), 7.03-7.49 (5H, Ph) ppm. ^{13}C NMR: δ = 162.2, 160.9 ($2\text{C}=\text{O}$), 146.7 ($\text{C}=\text{N}$), 146.0 (C), 138.5 (C), 127.9 (2CH), 124.0 (CH), 120.5 (2CH), 115.8 (CH), 62.9 (CH_2O), 14.7 (CH_3) ppm. MS: m/z (%) 291 (24, M^+), 264 (4), 142 (23), 135 (26), 107 (40), 5 (66), 77 (100), 57 (20), 44 (54). Anal. calcd. for $\text{C}_{13}\text{H}_{13}\text{N}_3\text{O}_3\text{S}$ (291.28): C, 53.55; H, 4.46; N, 14.01 %. Found: C, 51.38; H, 4.73; N, 16.01 %.

Methyl-3-amino-2-imino-4-oxo-1,3-thiazolan-5-ylidene acetate (3c): Yellow crystals; yield: 89 %, m.p. 180-181 °C. IR (KBr, $\nu_{\max}$, cm^{-1}): 3300, 3167 (NH_2), 1742, 1649 ($2\text{C}=\text{O}$), 1654 ($\text{C}=\text{C}$), 1606 ($\text{C}=\text{N}$). ^1H NMR: δ = 3.80 (s, MeO), 4.81 (s, NH_2), 5.20 (s, NH), 7.11 (s, CH), ppm. ^{13}C NMR: δ = 164.2, 160.8 ($2\text{C}=\text{O}$), 145.6 ($\text{C}=\text{N}$), 141.1 (C), 133.8 (C), 122.3 (CH), 51.3 (MeO) ppm. MS: m/z (%) 201 (38, M^+), 170 (8), 142 (5), 126 (25), 85 (86), 56 (100), 44 (24). Anal. calcd. for $\text{C}_6\text{H}_7\text{N}_3\text{O}_3\text{S}$ (201.3): C, 35.82; H, 3.48; N, 20.89 %. Found: C, 35.74; H, 3.17; N, 21.74 %.

Ethyl-3-amino-2-imino-4-oxo-1,3-thiazolan-5-ylidene acetate (3d): Green yellow powder; yield: 96 %, m.p. 170-171 °C. IR (KBr, $\nu_{\max}$, cm^{-1}): 3294, 3153 (NH_2), 1727, 1648 ($2\text{C}=\text{O}$), 1680 ($\text{C}=\text{C}$), 1596 ($\text{C}=\text{N}$). ^1H NMR: δ = 1.33 (t, $^3J_{\text{HH}}$

= 7.1, Me), 4.36 (q, $^3J_{\text{HH}} = 7.1$, CH_2O), 4.80 (brs, NH_2), 5.21 (s, NH), 6.94 (s, CH) ppm. ^{13}C NMR: δ = 166.2, 163.9 ($2\text{C}=\text{O}$), 146.7 ($\text{C}=\text{N}$), 142.9 (C), 137.5 (C), 121.0 (CH), 60.5 (CH_2O), 16.4 (CH_3) ppm. MS: m/z (%) 215 (28, M^+), 170 (14), 142 (36), 135 (26), 107 (40), 85 (100), 57 (20), 44 (54). Anal. calcd. for $\text{C}_7\text{H}_9\text{N}_3\text{O}_3\text{S}$ (215.21): C, 39.01; H, 4.18; N, 19.53 %. Found: C, 38.48; H, 4.13; N, 21.41 %.

The structures of compounds were deduced from their elemental analyses and their IR, ^1H and ^{13}C NMR spectra. The mass spectra of these compounds displayed molecular ion peaks at the appropriate m/z -values. The ^1H NMR spectrum, of **3a** in CDCl_3 showed three singlets for methoxy δ = 3.80, amino δ = 4.79 and olefinic δ = 7.08 protons δ , along with multiplets δ = 7.13 - δ = 7.66 for the aromatic protons. The ^{13}C NMR spectra of **3a** showed ten signals in agreement with the proposed structure. Partial assignments of these resonance are given in the experimental section. The ^1H and ^{13}C NMR spectra of **3b-3d** are similar to those for **3a**, except for the ester and aryl moieties, which exhibit characteristic signals at appropriate chemical shift. On the basis of well established chemistry of electrophilic acetylenes it is reasonable to assume that compounds **3** results from the initial conjugate addition of the sulfur atom of **1** to the acetylenic ester and the subsequent conversion of the 1:1 adduct to **3**. Then the ester group of intermediate **3** is attacked by the amino moiety to yield **3** by elimination of ROH (**Scheme-III**). When the bulky di-*tert*-butylacetylenedicarboxylate is used, the steric hindrance prevent the usual mechanism and the adduct product is not reasonable. In conclusion, we have prepared novel thiazolidine-4-one derivatives *via* one-pot reaction between 4-phenylthiosemicarbazide and thiosemicarbazide with dialkyl acetylene dicarboxylate. The present method carries the advantage that, not only is the reaction performed under neutral conditions, but the substances can be mixed without any activation or modification.

Scheme-III: Mechanism of reaction

ACKNOWLEDGEMENTS

Financial support for this work by the Research Council of Islamic Azad University, Tonekabon Branch, is gratefully acknowledged.

REFERENCES

- G.R. Newkome and A. Nayak, *Adv. Heterocycl. Chem.*, **25**, 83 (1979).
- S.J. Shah, S.R. Shah and N.C. Desai, *J. Indian Chem. Soc.*, **61**, 648 (1984).
- M.P. Dave, J.M. Patel and N.L. Langalia, *J. Indian Chem. Soc.*, **61**, 891 (1984).
- R.J. Boyce and G.C. Mulqueen, *Tetrahedron Lett.*, **35**, 5705 (1994).
- N. Karali, E. Ilhan, A. Gursay and M. Kiraz, *IL Farmaco*, **53**, 346 (1998).
- H.T. Fahmy, *Boll. Chim. Farm.*, **140**, 422 (2001).
- C.J. Andres, J.J. Bronson, S.V. D'Andrea, M.S. Deshpande, P.J. Falk, K.A. Grant-Young and W.E. Harte, *Bioorg. Med. Chem. Lett.*, **10**, 715 (2000).
- S.G. Kucukguzel, E.E. Oruc, S. Rollas, F. Sahin and A. Ozbek, *Eur. J. Med. Chem.*, **37**, 197 (2002).
- N. Ergenc and G. Capan, *IL Farmaco*, **49**, 133 (1994).
- G. Capan, N. Ergenc, A.C. Ekinici and A. Vidin, *IL Farmaco*, **51**, 729 (1996).
- G.C. Look, J.R. Schullek, C.P. Homes, J.P. Chinn, E.M. Ordon and M.A. Gallop, *Bioorg. Med. Chem. Lett.*, **6**, 707 (1996).
- J.J. Bhatt, B.R. Shah, H.P. Shah, P.B. Trivedi, N.K. Undavia and N.C. Desai, *Indian J. Chem.*, **33**, 189 (1994).
- L. Bukowski, M. Janowiec, Z. Zwolska-Kwiek, Z. Andrezejczyk, *Pharmazie*, **53**, 373 (1998).
- F.L. Gouveia, R.M.B. de Oliveira, T.B. de Oliveira, I.M. da Silva, S.C. do Nascimento, K.X.F.R. de Sena, J.F.C. de Albuquerque, *Eur. J. Med. Chem.*, **44**, 2038 (2009).
- N. Ulusoy, *Arzneim-Forsch-Drug Res.*, **52**, 565 (2002).
- K. Babaoglu, M.A. Page, V.C. Jones, M.R. McNeil, C. Dong, J.H. Naismith and R.E. Lee, *Bioorg. Med. Chem. Lett.*, **13**, 3227 (2003).
- M.V. Diurno, O. Mazzoni, P.E. Calignano, F. Giordano and A. Bolognese, *J. Med. Chem.*, **35**, 2910 (1992).
- M.L. Barreca, A. Chimirri, L. De Luca, A.M. Monforte, P. Monforte, A. Rao and M. Zappala, *Bioorg. Med. Chem. Lett.*, **11**, 1793 (2001).
- M.L. Barreca, J. Balzarini, A. Chimirri, E. De Clercq, L. De Luca, H.D. Holtje, M. Holtje, A.M. Monforte, P. Monforte, C. Pannecouque, A. Rao and M. Zappala, *J. Med. Chem.*, **45**, 5410 (2002).
- J. Balzarini, B. Orzeszko, J.K. Maurin and A. Orzeszko, *Eur. J. Med. Chem.*, **42**, 993 (2007).
- J. Balzarini, B. Orzeszko-Krzesin'ska, J.K. Maurin, A. Orzesz, *Eur. J. Med. Chem.*, **44**, 303 (2009).
- E. De Clercq, *Trends Pharmacol. Sci.*, **11**, 198 (1990).
- E. De Clercq, *J. Med. Chem.*, **48**, 1297 (2005).
- P. Wipf and P.C. Fritch, *Tetrahedron Lett.*, **35**, 5397 (1994).
- J.Y. Lai, J. Yu and B. Mekonnen, *Tetrahedron Lett.*, **37**, 7167 (1996).
- M.H. Shih and F.Y. Ke, *Bioorg. Med. Chem.*, **12**, 4633 (2004).
- A. Rao and A. Carbone, *IL Farmaco*, **57**, 747 (2002).
- R. Lakhan and R.L. Singh, *J. Agric. Food Chem.*, **39**, 580 (1991).
- V. Murugesan, V.S. Tiwari, R. Saxena, R. Tripathi, R. Paranjape, S. Kulkarni, N. Makwana, R. Suryawanshi and S.B. Katti, *Bioorg. Med. Chem.*, **19**, 6919 (2011).
- S.G. Modha and V.P. Mehta, *Mol. Divers.*, **14**, 767 (2010).
- A. Rao, J. Balzarini and A. Chimirri, *IL Farmaco*, **59**, 33 (2004).
- I. Yavari, Z. Hossaini, M. Sabbaghan, K. Porshamsian, M. Bagheri and S. Ali-Asgari, *Mol. Divers.*, **11**, 81 (2007).
- I. Yavari, K. Porshamsian, M. Bagheri and S. Ali-Asgari, *J. Sulfur Chem.*, **28**, 1 (2007).
- Kh. Pourshamsian, N. Montazeri, Rad-Moghadam and K.S. Aliasgari, *J. Heterocycl. Chem.*, **47**, 1439 (2010).